Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation

Eur Heart J Qual Care Clin Outcomes. 2018 Oct 1;4(4):328-329. doi: 10.1093/ehjqcco/qcx044.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Factor Xa Inhibitors / therapeutic use
  • Female
  • Humans
  • Incidence
  • Male
  • Rivaroxaban / therapeutic use*
  • Stroke / epidemiology
  • Stroke / etiology
  • Stroke / prevention & control*
  • Treatment Outcome
  • United States / epidemiology
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Warfarin
  • Rivaroxaban